12 Most Promising Biotech Stocks According to Wall Street Analysts

Page 2 of 10

9. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Analyst Upside: 39.68% 

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company specializing in neuroscience and oncology, focusing on treatments for serious diseases with limited therapeutic options, such as narcolepsy, epilepsy, and certain cancers.

At the American Epilepsy Society 2024 conference on December 6, 2024, Jazz Pharmaceuticals plc (NASDAQ:JAZZ)  presented fresh Epidiolex (cannabidiol) research that demonstrated its advantages beyond seizure management. Research has shown that patients with epilepsy and tuberous sclerosis complex (TSC) had improved emotional well-being, communication, and cognitive abilities. Most nurses and caregivers continued treatment, reporting better quality of life and fewer seizures. Epidiolex’s broad-spectrum efficacy was further supported by the EpiCom trial, which revealed that it also decreased behavioral problems in TSC patients.

With over $4 billion in revenue and significant growth across its sleep, epilepsy, and oncology portfolios—all of which generate over $1 billion annually—Jazz Pharmaceuticals plc (NASDAQ:JAZZ) had a successful 2024. The FDA’s expedited approval of Ziihera for HER2+ biliary tract cancer and encouraging developments in late-stage pipeline assets were among the company’s significant accomplishments. With $3 billion in cash at the end of 2024 and a voluntary $750 million debt payoff, the company strengthened its position for further expansion in 2025.

Wall Street analysts maintain a Strong Buy rating on the stock. Over the past three months, 18 analysts have set a 12-month average price target of $193.82, with estimates ranging from $150.00 to $230.00. This suggests a potential 39.68% increase from the current price of $138.76.

Page 2 of 10